ArticleCancer biomarkers : section A of Disease markers
Collagen turnover biomarkers as diagnostic, prognostic, and therapy monitoring indicators in gastric cancer.
Article in Cancer biomarkers : section A of Disease markers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundCirculating collagen turnover markers, including reC1M, PRO-C3, C3M, C4G, PRO-C8, TUM, PRO-C11, and PRO-C17, may serve as non-invasive biomarkers in gastric cancer (GC).MethodsEight serum collagen turnover markers were quantified in 74 pretreated GC patients from the SUNCASE trial and compared to 50 healthy donors. Markers were assessed at baseline and longitudinally after the first and second chemotherapy cycle. Diagnostic accuracy was evaluated by AUROC analysis; prognostic value was assessed for overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier and Cox regression analyses.ResultsAll markers except C4G were significantly elevated in GC patients vs. controls (p < 0.001). C3M showed the strongest diagnostic performance (AUROC 0.88, 95% CI 0.81-0.95; sensitivity 78%, specificity 77%). Elevated reC1M (HR 2.70), C3M (HR 2.33), PRO-C11 (HR 2.14), and TUM (HR 2.09) were independently prognostic of shorter OS. None of the established tumor markers (CA 19-9, CEA, CA 72-4) retained prognostic significance. Longitudinally, a >20% reduction in PRO-C3 and PRO-C11 after the first chemotherapy cycle was associated with longer OS.ConclusionCollagen turnover markers reC1M, C3M, TUM, and PRO-C11 are independent prognostic markers for OS in advanced GC. C3M demonstrated the highest diagnostic accuracy in distinguishing GC patients from healthy controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.